Are you Dr. Link?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 75 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
200 Hawkins Dr
Iowa City, IA 52242Phone+1 319-353-8504Fax+1 319-353-8383
Summary
- Dr. Brian Link, MD is an oncologist in Iowa City, Iowa. He is currently licensed to practice medicine in Iowa and Illinois. He is affiliated with University of Iowa Hospitals and Clinics and is a Professor of Hematology & Oncology at University Iowa College of Medicine.
Education & Training
University of Iowa Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 1990 - 1993
Rush University Medical CenterResidency, Internal Medicine, 1986 - 1990
University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 1986
Certifications & Licensure
IA State Medical License 1990 - 2026
IL State Medical License 1988 - 1990- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated Start of enrollment: 2004 Jul 01
- Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma Start of enrollment: 2006 Jul 01
- Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma Start of enrollment: 2013 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 91 citationsMolecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements.Rebecca A. Luchtel, Surendra Dasari, Naoki Oishi, Martin Bjerregård Pedersen, Guangzhen Hu
Blood. 2018-09-27 - 47 citationsRecurrent MSCE116K mutations in ALK-negative anaplastic large cell lymphoma.Rebecca A. Luchtel, Michael T. Zimmermann, Guangzhen Hu, Surendra Dasari, Manli Jiang
Blood. 2019-06-27 - 53 citationsPrimary Breast Lymphoma in the United States: 1975-2013.Alexandra Thomas, Brian K. Link, Sean Altekruse, Paul A. Romitti, Mary C. Schroeder
Journal of the National Cancer Institute. 2017-06-01
Press Mentions
Non-Chemo Option for Relapsed Indolent LymphomasJune 26th, 2019
Grant Support
- Clinical ResearchNational Cancer Institute2007–2009
- Clinical Trials Support CoreNational Cancer Institute2005–2009
- CPG 7909 In Patients With B-Cell Non-Hodgkin'S LymphomaNational Center For Research Resources2004
- Effector Cells And Antilymphoma Antibody TherapyNational Cancer Institute2002
- Core--Clinical TrialsNational Cancer Institute2002
- HU 1d10 MAB In Relapsed Non-Hodgkin'S Lymphoma (NHL)National Center For Research Resources2000–2002
- Core--Clinical Trials Support GroupNational Cancer Institute2000–2002
- Idec C2b8 In Combination With CHOP Chemotherapy In Nonhodgkins LymphomasNational Center For Research Resources1998–1999
- Administration Of Idec C2b8 With Interferon Alpha In Patients With LymphomaNational Center For Research Resources1998–1999
- IDEC-C2B8 In Combination With CHOP Chemotherapy In Nonhodgkins LymphomasNational Center For Research Resources1997
- Administration Of IDEC-C2B8 With Interferon Alpha In Patients With LymphomaNational Center For Research Resources1997
Professional Memberships
- Member
